A011801 CompassHER2

Breast Cancer

COMPASS HER2 Trials Examining Escalating and De-Escalating Therapy in HER2-positive Breast Cancer: Optimizing Treatment in Residual Disease (COMPASS HER2-RD): A Double-Blinded, Phase III Randomized Trial

Key Team Members

Principal Investigator

Steven A. Madden, MD

Research Coordinator

Katharine "Kate" Madden

Accepting Patients

Check if You’re Eligible

(803) 935-8300

Research@lexhealth.org

About the Trial

The purpose of this study is to compare the usual treatment with T-DM1 alone to T-DM1 plus tucatinib. The addition of tucatinib to the usual treatment could prevent the breast cancer from returning.